Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | CASR | P41180 | 2/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253948 | 1.00 | TDP1 (0.40) | TDP1GAAALDH1A1ALPLCASR | |
| SCHEMBL252984 | 0.92 | TDP1 (0.37) | TDP1GAAALDH1A1ALPLCASR | |
| SCHEMBL251262 | 0.87 | TDP1 (0.36) | TDP1GAAALDH1A1LMNANR3C2 | |
| SCHEMBL251261 | 0.87 | TDP1 (0.36) | TDP1GAAALDH1A1LMNANR3C2 | |
| SCHEMBL252646 | 0.87 | TDP1 (0.34) | TDP1ALDH1A1CASRLMNAHPGD | |
| SCHEMBL252645 | 0.87 | TDP1 (0.34) | TDP1ALDH1A1CASRLMNAHPGD | |
| SCHEMBL14859955 | 0.84 | TDP1 (0.34) | TDP1GAAALDH1A1LMNACASP3 | |
| SCHEMBL14860189 | 0.84 | TDP1 (0.34) | TDP1GAAALDH1A1LMNACASP3 | |
| SCHEMBL251291 | 0.84 | ALDH1A1 (0.32) | TDP1ALDH1A1LMNACASP3 | |
| SCHEMBL3414301 | 0.84 | TDP1 (0.34) | TDP1GAAALDH1A1LMNACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588469-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2012003271-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096134-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | TDP1 2619/4885GAA 3005/4885ALDH1A1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.